By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Acetylon Pharmaceuticals 



Boston  Massachusetts    U.S.A.
Phone: 617-435-2664 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Acetylon Pharmaceuticals Announces The Presentation Of Preclinical Data At AACR Supporting The Use Of Selective HDAC6 Inhibition To Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 4/20/2016 11:32:03 AM
Acetylon Pharmaceuticals Presents Data From Three Phase Ib Studies Of Ricolinostat (ACY-1215) For The Treatment Of Lymphoma And Multiple Myeloma 12/7/2015 10:36:02 AM
Acetylon Pharmaceuticals Presents Data On The Use Of HDAC 6 Inhibitors Ricolinostat (ACY-1215) And ACY-241 In Combination With Pomalidomide For The Treatment Of Multiple Myeloma 12/7/2015 10:18:33 AM
Acetylon Pharmaceuticals Presents Data On The Pharmacokinetics And Hbe/Hbg Hemoglobin Induction Following Once Daily Dosing Of An Oral HDAC1,2 Inhibitor In Animal Models 12/7/2015 10:17:20 AM
Acetylon Pharmaceuticals’s Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-Tumor Activity Of Paclitaxel In Preclinical Solid Tumor Models 11/6/2015 8:10:15 AM
Acetylon Pharmaceuticals To Present At BioPharm America 2015 9/14/2015 3:10:26 PM
Acetylon Pharmaceuticals Presented Positive Preliminary Data From Phase 1b/2 Trial Of Ricolinostat In Combination With Pomalyst As Potential Oral Treatment For Patients With Multiple Myeloma 6/16/2015 11:47:06 AM
Acetylon Pharmaceuticals Presents Data On Synergistic Activity Of Selective HDAC6 Inhibition In Preclinical Models Of Multiple Myeloma And Mantle Cell Lymphoma At The AACR Annual Meeting 4/22/2015 8:44:05 AM
Acetylon Pharmaceuticals Announces Preclinical Anti-Cancer Activity Of Selective HDAC1/2 Inhibitors In Neuroblastoma And Acute Myeloid Leukemia 4/20/2015 1:05:32 PM
Acetylon Pharmaceuticals Presents At The Wells Fargo Celgene Partnership Forum 1/22/2015 10:55:50 AM
12345
//-->